Q0249 HCPCS Level II code: Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and…
Q0249 is the HCPCS code for “Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen…” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
Q0249Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg
Short description: Tocilizumab for covid-19
HCPCS · United States
Medicare details
The indicators CMS publishes with Q0249 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Vaccinations
- Type of service
- Pneumococcal/flu vaccine
- BETOS category
- Immunizations/Vaccinations
- Added
- Jun 24, 2021
Where Q0249 sits
- 1Q codesTemporary codes
- 2Active code Q0249Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code Q0249 mean?
Q0249 is the HCPCS code for “Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover Q0249?
CMS lists Q0249’s Medicare coverage as “Carrier judgment” and its pricing as “Vaccinations”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside Q0249
All Q codesQ0239Injection, bamlanivimab-xxxx, 700 mgQ0240Injection, casirivimab and imdevimab, 600 mgQ0243Injection, casirivimab and imdevimab, 2400 mgQ0244Injection, casirivimab and imdevimab, 1200 mgQ0245Injection, bamlanivimab and etesevimab, 2100 mgQ0247Injection, sotrovimab, 500 mgQ0477Power module patient cable for use with electric or electric/pneumatic ventricular assist device, replacement onlyQ0478Power adapter for use with electric or electric/pneumatic ventricular assist device, vehicle typeQ0479Power module for use with electric or electric/pneumatic ventricular assist device, replacement onlyQ0480Driver for use with pneumatic ventricular assist device, replacement onlyQ0481Microprocessor control unit for use with electric ventricular assist device, replacement onlyQ0482Microprocessor control unit for use with electric/pneumatic combination ventricular assist device, replacement only